Lexicon Pharmaceuticals, Inc.  

(Public, NASDAQ:LXRX)   Watch this stock  
Find more results for LXRX
12.69
+0.56 (4.62%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 11.92 - 12.70
52 week 5.60 - 13.88
Open 12.05
Vol / Avg. 632,149.00/2.27M
Mkt cap 1.26B
P/E     -
Div/yield     -
EPS -1.13
Shares 103.61M
Beta 1.94
Inst. own 97%
Nov 2, 2015
Q3 2015 Lexicon Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Aug 12, 2015
Lexicon Pharmaceuticals Inc at Wedbush PacGrow Healthcare Conference
Aug 7, 2015
Q2 2015 Lexicon Pharmaceuticals Inc Earnings Release
Aug 7, 2015
Q2 2015 Lexicon Pharmaceuticals Inc Earnings Call
Aug 3, 2015
Lexicon Pharmaceuticals Reports Positive Top-Line Results For Pivotal Phase 3 Telotristat Etiprate Study In Cancer Patients With Carcinoid Syndrome Corporate Call
Jun 3, 2015
Lexicon Pharmaceuticals Inc at Jefferies Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin -7466.49% -438.85%
Operating margin -7097.87% -439.16%
EBITD margin - -348.46%
Return on average assets -26.17% -26.91%
Return on average equity -46.05% -44.16%
Employees 106 -
CDP Score - -

Address

8800 Technology Forest Pl
THE WOODLANDS, TX 77381-1160
United States - Map
+1-281-8633000 (Phone)
+1-281-8638088 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Lexicon Pharmaceuticals, Inc. (Lexicon) is a biopharmaceutical company. The Company is focused on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company's telotristat etiprate is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome. It has completed two Phase II clinical trials and is conducting a single Phase III clinical trial of telotristat etiprate in carcinoid syndrome patients. The Company's sotagliflozin is an orally delivered small molecule drug candidate, as a treatment for type 1 and type 2 diabetes. The Company has completed two Phase II clinical trials of sotagliflozin in type 2 diabetes patients and an additional clinical trial of sotagliflozin in type 2 diabetes patients with renal impairment. It has also completed a Phase II clinical trial of sotagliflozin in type 1 diabetes patients.

Officers and directors

Raymond Debbane Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Lonnel Coats President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Jeffrey L. Wade J.D. Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
Age: 50
Bio & Compensation  - Reuters
Pablo Lapuerta M.D. Executive Vice President, chief medical officer
Age: 51
Bio & Compensation  - Reuters
Alan J. Main Ph.D. Executive Vice President - CMC and supply operations
Age: 61
Bio & Compensation  - Reuters
James F. Tessmer Vice President - Finance & Accounting
Age: 55
Bio & Compensation  - Reuters
John Northcott Vice President - Marketing, Commercial Strategy and Operations
Age: 37
Bio & Compensation  - Reuters
Philippe J. Amouyal Independent Director
Age: 57
Bio & Compensation  - Reuters
Samuel L. Barker Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Robert J. Lefkowitz M.D. Independent Director
Age: 71
Bio & Compensation  - Reuters